WillItSurvive
Pharma and healthcare groups · subsidiary of KKR (controlling shareholder, 54-77% stake as of Feb 2025) · India

HealthCare Global Enterprises

hcgoncology.com ↗

Indian pure-play cancer hospital chain, 30+ centers, 2,500+ beds, 19 cities plus Nairobi.

Defensible for now
Assessed 26 July 2026 · Evidence as of 26 July 2026
Real protection, with named pressure against it.
On the recordSince 26 July 2026 · Checkable from around July 30, 2026 · Every call on the record Checkpoint: Q1 FY27 earnings release, expected to clarify the undisclosed FY26 'strategic divestment' and margin trend
The call

HCG keeps growing and deleveraging as a specialist under new KKR ownership, while general hospital chains build their own cancer units around it.

HealthCare Global Enterprises runs over 30 cancer hospitals across India and Africa with 2,500 beds and 400 cancer doctors, and it is making money and shrinking its debt. The real problem is that huge hospital chains like Apollo, Max, and Fortis are building their own cancer centers and taking patients away, so HCG's advantage as a cancer specialist is turning into just a head start. The next big clue will come in late July 2026 when the company reports earnings, which should show whether HCG is still keeping up with its giant competitors or slowly losing ground.

Why
01
AI pressure: None apparent. AI diagnostic tools are entering oncology workflows generally, but no specific AI product is displacing HCG's physical treatment centers. Could AI do the core job? Unlikely.
02
Bigger players: Apollo Hospitals (and Max, Fortis) building out oncology units. Apollo runs 13 comprehensive cancer centers with proton therapy; Max and Fortis are growing oncology revenue fast, competing directly for the same patients. Could a giant copy it? Probably.
03
What protects it. Decades of oncology-only focus, 400+ specialist oncologists, and licensed treatment infrastructure that general hospitals are still building out.
What would change this call
HCG's Q1 FY27 earnings (~July 30, 2026) reveal detail on the undisclosed 'strategic divestment' flagged in FY26 results. Shows whether ownership/capital allocation is pruning opportunistically or retrenching under pressure.
Apollo, Max, or Fortis report oncology-segment growth exceeding HCG's revenue growth for 2+ consecutive quarters. Would confirm HCG's specialist moat is a temporary head-start, not a durable wall.
CVC continues open-market sell-down of HCG shares through 2026 without new strategic buyer emerging. Would signal fading confidence from a major existing shareholder in HCG's standalone trajectory.
Key numbers
  • FY26 revenue Rs 25,454 million, up 15% YoY (2026-03-31)
  • FY26 EBITDA margin 18.5%, Adjusted EBITDA Rs 4,711 million (2026-03-31)
  • Net debt down to 1.4x EBITDA (2026-03-31)
Named risks
  • Multispecialty giants Apollo, Max and Fortis are building comparable oncology capacity, eroding HCG's specialist moat. Severity: high
  • Undisclosed FY26 'strategic divestment' referenced in results with no public details on scope or intent. Severity: medium
  • CVC continuing to sell shares in open market as of May 2026 signals unresolved ownership transition. Severity: medium
  • Q3 FY26 net loss driven by labor-code cost changes shows margin volatility despite revenue growth. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Apollo Hospitalscontesting13 comprehensive cancer centers with proton therapy, ~₹1,900 crore oncology revenue FY25 (2025-03-31)
Max Healthcaregaining onOncology ~25% of inpatient revenue (~₹1,560 crore) in first nine months FY26 (to 2025-12-31)
Fortis Healthcaregaining onOncology revenue +28% YoY in Q1 FY26 (2025-06-30), outpacing HCG's overall growth
Questions people ask
Is HealthCare Global Enterprises (HCG) profitable in 2026?
Yes. HCG's FY26 (year ended March 31, 2026) Adjusted PAT rose 25% YoY to ₹557 million, with Adjusted EBITDA of ₹4,711 million at an 18.5% margin and net debt reduced to 1.4x EBITDA, per its own investor disclosures dated June 22, 2026.
Who owns HealthCare Global Enterprises now?
KKR signed definitive agreements on February 23, 2025 to acquire up to 54% of HCG from CVC Asia V for about $400 million at INR 445/share, stating no intention to delist. The stock still traded actively on NSE/BSE as of July 24, 2026.
Could AI replace doctors at HCG's cancer hospitals?
No. Cancer treatment requires physical surgery, radiation and chemotherapy delivery that AI cannot perform. HCG itself began using AI in late 2024 via an Accenture partnership for image analysis and personalizing treatment for head-and-neck and GI cancers, not replacing clinicians.
Who is HealthCare Global Enterprises' biggest competitor?
Apollo Hospitals is HCG's largest rival, operating 13 Comprehensive Cancer Centres with South Asia's first proton therapy and generating about ₹1,900 crore in oncology revenue in FY25 (ended March 2025), far exceeding HCG's scale.
Is HCG's revenue growing faster or slower than rival hospital chains' oncology units?
HCG's FY26 revenue grew 15% YoY to ₹25,454 million (year ended March 31, 2026), while Fortis Healthcare's oncology segment grew 28% YoY in Q1 FY26, suggesting multispecialty rivals are growing their oncology businesses faster than HCG's overall growth rate.
Is HCG at risk of being delisted from Indian stock exchanges?
KKR's February 23, 2025 public announcement stated it had no intention to delist HCG via its open offer, and the stock continued trading actively on NSE and BSE with a market cap around ₹99,517 million as of July 24, 2026.
Timeline
  • 2026-05Morgan Stanley, Nippon India MF buy ~63 lakh HCG shares (~Rs 438 crore) from CVC in open market
  • 2026-03-31FY26 results: revenue ₹25,454 million (+15%), EBITDA margin 18.5%, PAT +25% to ₹557 million
  • 2025-12-31Q3 FY26: revenue +13%, EBITDA +20%, but net loss due to labor-code cost changes
  • 2025-05Management flags planned Orbitrap Astral Mass Spectrometer acquisition for precision diagnostics
  • 2025-03-31FY25 results: revenue ₹22,228 million (+16%), EBITDA ₹3,974 million (17.9% margin)
  • 2025-02-23KKR signs deal to acquire up to 54% of HCG from CVC for ~$400 million, no delisting intent
  • 2024-12HCG acquires majority stake in Vizag's Mahatma Gandhi Cancer Hospital for ₹414 crore EV
  • 2024-12HCG partners with Accenture to deploy AI image-analysis and informatics for cancer data
Revision history
26 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources